ArticleStatistics in medicine2014
Analyzing longitudinal data to characterize the accuracy of markers used to select treatment.
Article in Statistics in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Measures of Performance and Clinical Superiority Thresholds for 'Test-and-treat' Predictive Biomarkers.Applied health economics and health policy · 2025Article
- Sensitivity, Specificity, PPV, and NPV for Predictive Biomarkers.Journal of the National Cancer Institute · 2015Article
- The Fundamental Difficulty With Evaluating the Accuracy of Biomarkers for Guiding Treatment.Journal of the National Cancer Institute · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
With the increasing availability of detailed clinical information, there is optimism that treatment choices can be selectively directed to those individuals most likely to benefit. While standard clinical trials can establish whether a treatment appears to be effective on average, subsequent work is needed to determine whether there are identifiable subgroups of subjects for whom treatment is either particularly beneficial or harmful. Molecular assays and modern imaging technology now allow numerous candidate measures to be used as potential determinants of treatment choice. In this manuscript, we focus on novel measures of decision accuracy that reflect the treatment marker objective. Specifically, we define longitudinal individual-level potential outcomes (principal strata) that characterize patient outcomes under treated and untreated states. We propose generalizations of sensitivity and specificity that measure the accuracy with which a marker can distinguish those subjects who are expected to have a more favorable outcome under a specific treatment choice from those subjects who are expected to have a more favorable outcome under alternative treatment options. For quantitative markers, we propose principal receiver operating characteristic curves that display the full range of potential sensitivity and specificity. We use simulations to demonstrate the properties of proposed estimators, and we illustrate the methods using candidate neuroimaging and electrodiagnostic markers that could be used to select patients for carpal tunnel surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.